Get the Stockscreener App
0.769
4.63%
0.034
Avenue Therapeutics Inc stock is traded at $0.769, with a volume of 7,216.
It is up +4.63% in the last 24 hours and up +4.63% over the past month.
See More
Previous Close:
$0.735
Open:
$0.8
24h Volume:
7,216
Relative Volume:
11.24
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.2018
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
+4.63%
1M Performance:
+4.63%
6M Performance:
-83.79%
1Y Performance:
-96.88%
1-Day Range:
$0.7588
$0.80
1-Week Range:
$0.7588
$0.80
52-Week Range:
$0.5231
$0.80
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.769 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares By Investing.com - Investing.com Canada
Axsome therapeutics CEO Tabuteau sells $11.6 million in shares - Investing.com India
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - WV News
Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
Avenue Therapeutics Leads Six-Month Stock Performance with 267.29% Return - Markets Mojo
Axsome Therapeutics stock reaches all-time high of 152.94 USD By Investing.com - Investing.com Australia
Avenue Therapeutics Leads Six-Month Stock Performance with 253.98% Return - Markets Mojo
Avenue Therapeutics Leads Six-Month Stock Performance with 257.7% Return - Markets Mojo
Village Farms International Leads with 276.7% Return in Recent Six Months - Markets Mojo
Avenue Therapeutics Announces 2025 Annual Meeting Date - The Globe and Mail
[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event | ATXI SEC FilingForm 8-K - Stock Titan
Village Farms International Leads with 282% Return in Recent Performance Surge - Markets Mojo
Village Farms International Leads with 275% Return in Recent Performance Surge - Markets Mojo
Axsome Therapeutics stock hits all-time high at 144.19 USD By Investing.com - Investing.com Nigeria
Avenue Therapeutics Leads Six-Month Stock Performance with 333.85% Return - Markets Mojo
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Avenue Therapeutics Reports Improved Financials Amid Challenges - TipRanks
[10-Q] AVENUE THERAPEUTICS, INC. Quarterly Earnings Report | ATXI SEC FilingForm 10-Q - Stock Titan
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Village Farms International Leads Six-Month Stock Performance with 424.66% Return - Markets Mojo
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
Village Farms International Leads with 418.66% Return in Recent Performance - Markets Mojo
Axsome Therapeutics (AXSM) Receives a Buy from Mizuho Securities - The Globe and Mail
Village Farms International Leads with 354.34% Return in Recent Performance - Markets Mojo
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - MSN
Axsome Therapeutics Eyes Baergic Bio: Is This the Next Big CNS Breakthrough? - Smartkarma
Axsome Therapeutics Buys Global Rights To AZD7325 To Expand Epilepsy Pipeline - Pulse 2.0
Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN) - The Globe and Mail
Nebius Group NV Leads Six-Month Stock Performance with 359.83% Return - Markets Mojo
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate By Investing.com - Investing.com Australia
Avenue shares rights to epilepsy drug candidate with Axsome in deal - Investing.com Nigeria
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate - Investing.com India
Axsome Therapeutics stock hits all-time high at 139.22 USD By Investing.com - Investing.com South Africa
Axsome Therapeutics stock hits all-time high at 139.22 USD - Investing.com India
Avenue Therapeutics (ATXI) Sells Baergic Bio to Axsome Therapeutics - GuruFocus
AZN Secures Deal with Axsome for Epilepsy Drug Development - GuruFocus
Avenue shares rights to epilepsy drug candidate with Axsome in deal By Investing.com - Investing.com South Africa
Axsome Therapeutics IncObtains Exclusive G - 富途牛牛
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy - The Manila Times
OTC Markets Group Welcomes SUN SILVER LTD. to OTCQX - The Manila Times
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Cap:
|
Volume (24h):